Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Development and validation of a patient decision aid for prostate Cancer therapy: from paternalistic towards participative shared decision making.

Ankolekar A, Vanneste BGL, Bloemen-van Gurp E, van Roermund JG, van Limbergen EJ, van de Beek K, Marcelissen T, Zambon V, Oelke M, Dekker A, Roumen C, Lambin P, Berlanga A, Fijten R.

BMC Med Inform Decis Mak. 2019 Jul 11;19(1):130. doi: 10.1186/s12911-019-0862-4.

2.

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.

D'Agate S, Wilson T, Adalig B, Manyak M, Palacios-Moreno JM, Chavan C, Oelke M, Roehrborn C, Della Pasqua O.

World J Urol. 2019 May 11. doi: 10.1007/s00345-019-02783-x. [Epub ahead of print]

PMID:
31079189
3.

[Acute urinary retention in men: efficacy of alpha-blockers in catheter removal after urinary retention].

Mühlstädt S, Oelke M.

Urologe A. 2019 Jun;58(6):680-685. doi: 10.1007/s00120-019-0945-y. Review. German. No abstract available.

PMID:
31069453
4.

What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.

Oelke M, Addali M, Reisenauer C.

Arch Gynecol Obstet. 2019 May;299(5):1243-1252. doi: 10.1007/s00404-019-05127-7. Epub 2019 Apr 2. Review.

PMID:
30941558
5.

A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.

Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, Amarenco G, Gamé X, Kirby R, Van Der Aa F, Cornu JN.

Eur Urol. 2019 Jun;75(6):988-1000. doi: 10.1016/j.eururo.2019.02.038. Epub 2019 Mar 26. Review.

PMID:
30922690
6.

The development of the ICIQ-UAB: A patient reported outcome measure for underactive bladder.

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Lasch K, Stroupe A, Deshpande C, Delbecque L, Van Koeveringe G, Oelke M, Belal M, Bosch R, Blok B, Nitti V, Gotoh M, Takei M, Crawford B, Klaver M, Bongaerts D, Hakimi Z, Kos T, Abrams P.

Neurourol Urodyn. 2019 Mar;38(3):996-1004. doi: 10.1002/nau.23947. Epub 2019 Feb 22.

PMID:
30801826
7.

[Diagnostic procedures and diagnostic strategy for lower urinary tract symptoms/benign prostatic hyperplasia : An overview].

Bschleipfer T, Oelke M, Rieken M.

Urologe A. 2019 Mar;58(3):238-247. doi: 10.1007/s00120-019-0870-0. Review. German.

PMID:
30796463
8.

[Fake News BPH - what is really true!]

Oelke M, Bschleipfer T, Höfner K.

Urologe A. 2019 Mar;58(3):271-283. doi: 10.1007/s00120-019-0885-6. Review. German.

PMID:
30790005
9.

The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction.

D'Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, Hamid R, Homma Y, Marcelissen T, Rademakers K, Schizas A, Singla A, Soto I, Tse V, de Wachter S, Herschorn S; Standardisation Steering Committee ICS and the ICS Working Group on Terminology for Male Lower Urinary Tract & Pelvic Floor Symptoms and Dysfunction.

Neurourol Urodyn. 2019 Feb;38(2):433-477. doi: 10.1002/nau.23897. Epub 2019 Jan 25. Review.

PMID:
30681183
10.

Selective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression.

Bak S, Tischer S, Dragon A, Ravens S, Pape L, Koenecke C, Oelke M, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B.

Front Immunol. 2018 Dec 17;9:2953. doi: 10.3389/fimmu.2018.02953. eCollection 2018.

11.

Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB).

Chapple CR, Osman NI, Birder L, Dmochowski R, Drake MJ, van Koeveringe G, Nitti VW, Oelke M, Smith PP, Yamaguchi O, Wein A, Abrams P.

Neurourol Urodyn. 2018 Nov;37(8):2928-2931. doi: 10.1002/nau.23701. Epub 2018 Sep 11. No abstract available.

PMID:
30203560
12.

Correction: Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.

Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP.

Oncotarget. 2018 Aug 17;9(64):32401. doi: 10.18632/oncotarget.26018. eCollection 2018 Aug 17.

13.

Soluble MHC class I complexes for targeted immunotherapy.

Schappert A, Schneck JP, Suarez L, Oelke M, Schütz C.

Life Sci. 2018 Sep 15;209:255-258. doi: 10.1016/j.lfs.2018.08.023. Epub 2018 Aug 10. Review.

14.

Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.

Ferreira RS, D'Ancona CAL, Oelke M, Carneiro MR.

Einstein (Sao Paulo). 2018 Aug 6;16(3):eAO4207. doi: 10.1590/S1679-45082018AO4207. English, Portuguese.

15.

[Nocturia in men with benign prostatic hyperplasia].

Oelke M, Fangmeyer B, Zinke J, Witt JH.

Aktuelle Urol. 2018 Aug;49(4):319-327. doi: 10.1055/a-0650-3700. Epub 2018 Aug 7. German.

PMID:
30086589
16.

Renal cell cancer after kidney transplantation.

Kleine-Döpke D, Oelke M, Schwarz A, Schwager Y, Lehner F, Klempnauer J, Schrem H.

Langenbecks Arch Surg. 2018 Aug;403(5):631-641. doi: 10.1007/s00423-018-1694-x. Epub 2018 Jul 12.

PMID:
30003323
17.

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

Goldman HB, Oelke M, Kaplan SA, Kitta T, Russell D, Carlsson M, Arumi D, Mangan E, Ntanios F.

Int Urogynecol J. 2019 Feb;30(2):239-244. doi: 10.1007/s00192-018-3640-4. Epub 2018 Mar 29.

PMID:
29600400
18.

Cord blood-derived T cells allow the generation of a more naïve tumor-reactive cytotoxic T-cell phenotype.

Kwoczek J, Riese SB, Tischer S, Bak S, Lahrberg J, Oelke M, Maul H, Blasczyk R, Sauer M, Eiz-Vesper B.

Transfusion. 2018 Jan;58(1):88-99. doi: 10.1111/trf.14365. Epub 2017 Oct 11.

PMID:
29023759
19.

A practical approach to the management of nocturia.

Oelke M, De Wachter S, Drake MJ, Giannantoni A, Kirby M, Orme S, Rees J, van Kerrebroeck P, Everaert K.

Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13027. Epub 2017 Oct 5. Review.

20.

Influence of Linguistic and Nonlinguistic Variables on Generalization and Maintenance Following Phonomotor Treatment for Aphasia.

Pompon RH, Bislick L, Elliott K, Madden EB, Minkina I, Oelke M, Kendall D.

Am J Speech Lang Pathol. 2017 Nov 8;26(4):1092-1104. doi: 10.1044/2017_AJSLP-16-0175.

PMID:
28832881
21.

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.

Tubaro A, Batista JE, Nitti VW, Herschorn S, Chapple CR, Blauwet MB, Siddiqui E, Huang M, Oelke M.

Ther Adv Urol. 2017 May 10;9(6):137-154. doi: 10.1177/1756287217702797. eCollection 2017 Dec.

22.

Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies.

Drake MJ, Oelke M, Snijder R, Klaver M, Traudtner K, van Charldorp K, Bongaerts D, Van Kerrebroeck P.

PLoS One. 2017 Feb 6;12(2):e0170726. doi: 10.1371/journal.pone.0170726. eCollection 2017.

23.

A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.

Wagg A, Arumi D, Herschorn S, Angulo Cuesta J, Haab F, Ntanios F, Carlsson M, Oelke M.

Age Ageing. 2017 Jul 1;46(4):620-626. doi: 10.1093/ageing/afw252.

PMID:
28057620
24.

Validating the Communicative Participation Item Bank (CPIB) for use with people with aphasia: an analysis of Differential Item Function (DIF).

Baylor C, Oelke M, Bamer A, Hunsaker E, Off C, Wallace SE, Pennington S, Kendall D, Yorkston K.

Aphasiology. 2017;31(8):861-878. doi: 10.1080/02687038.2016.1225274. Epub 2016 Sep 9.

26.

[Erratum to: Generation Y - problem or solution in daily clinical practice].

Goebell P, Salem J, Struck JP, Stahl L, Oelke M, Sommerkamp HJ, Schwaibold R, Braun M, Berges R, Schöneberger M.

Urologe A. 2016 Nov;55(11):1486. German. No abstract available.

PMID:
27778043
27.
28.

Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.

Weidlich D, Andersson FL, Oelke M, Drake MJ, Jonasson AF, Guest JF.

Eur J Health Econ. 2017 Jul;18(6):761-771. doi: 10.1007/s10198-016-0826-x. Epub 2016 Sep 27.

29.

Deep Surgical Site Infections after Open Radical Cystectomy and Urinary Diversion Significantly Increase Hospitalisation Time and Total Treatment Costs.

Wolters M, Oelke M, Lutze B, Weingart M, Kuczyk MA, Chaberny IF, Graf K.

Urol Int. 2017;98(3):268-273. doi: 10.1159/000449472. Epub 2016 Sep 14.

PMID:
27622509
30.

Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.

Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP.

Oncotarget. 2016 Oct 18;7(42):68503-68512. doi: 10.18632/oncotarget.11785. Erratum in: Oncotarget. 2018 Aug 17;9(64):32401.

31.

Ultrasound detrusor wall thickness measurement in combination with bladder capacity can safely detect detrusor underactivity in adult men.

Rademakers KL, van Koeveringe GA, Oelke M; FORCE Research Group, Maastricht and Hannover.

World J Urol. 2017 Jan;35(1):153-159. doi: 10.1007/s00345-016-1902-7. Epub 2016 Jul 22.

PMID:
27447991
32.

[Generation Y : Problem or solution in daily clinical practice].

Goebell P, Salem J, Strunk J, Stahl L, Oelke M, Sommerkamp HJ, Schwaibold R, Braun M, Berges R, Schöneberger M.

Urologe A. 2016 Aug;55(8):1047-9. doi: 10.1007/s00120-016-0184-4. German. No abstract available. Erratum in: Urologe A. 2016 Oct 24;:.

PMID:
27411998
33.

Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men With Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases.

Brock G, Ni X, Oelke M, Mulhall J, Rosenberg M, Seftel A, D'Souza D, Barry J.

J Sex Med. 2016 May;13(5):860-75. doi: 10.1016/j.jsxm.2016.02.171.

34.

Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.

McVary KT, Peterson A, Donatucci CF, Baygani S, Henneges C, Clouth J, Wong D, Oelke M.

J Urol. 2016 Sep;196(3):824-30. doi: 10.1016/j.juro.2016.04.062. Epub 2016 Apr 19.

PMID:
27105760
35.

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL 2nd, Oelke M, Schneck JP, Webb TJ.

Clin Cancer Res. 2016 Aug 15;22(16):4249-58. doi: 10.1158/1078-0432.CCR-15-2518. Epub 2016 Apr 13.

36.

Prediction of sacral neuromodulation treatment success in men with impaired bladder emptying-time for a new diagnostic approach.

Rademakers KL, Drossaerts JM, van Kerrebroeck PE, Oelke M, van Koeveringe GA.

Neurourol Urodyn. 2017 Mar;36(3):808-810. doi: 10.1002/nau.23010. Epub 2016 Apr 6.

PMID:
27062496
37.

Effects of Tadalafil Once-Daily or On-Demand vs Placebo on Return to Baseline Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy--Results from a Randomized Controlled Trial (REACTT).

Mulhall JP, Brock G, Oelke M, Fode M, Probst KA, Henneges C, d'Anzeo G, Rossi A, Büttner H.

J Sex Med. 2016 Apr;13(4):679-83. doi: 10.1016/j.jsxm.2016.01.022. Epub 2016 Mar 25.

PMID:
27045264
38.

Granulocyte colony-stimulating factor impairs CD8(+) T cell functionality by interfering with central activation elements.

Bunse CE, Tischer S, Lahrberg J, Oelke M, Figueiredo C, Blasczyk R, Eiz-Vesper B.

Clin Exp Immunol. 2016 Jul;185(1):107-18. doi: 10.1111/cei.12794. Epub 2016 May 13.

39.

Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Postradiation Cystitis: Prospective Pilot Study.

Gacci M, Saleh O, Giannessi C, Chini T, Della Camera PA, Detti B, Livi L, Finazzi Agro E, Li Marzi V, Minervini A, Carini M, Oelke M, Gravas S, Serni S.

Clin Genitourin Cancer. 2016 Oct;14(5):444-449. doi: 10.1016/j.clgc.2016.01.016. Epub 2016 Feb 8.

PMID:
26953222
40.

Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.

Montorsi F, Oelke M, Henneges C, Brock G, Salonia A, d'Anzeo G, Rossi A, Mulhall JP, Büttner H.

Eur Urol. 2016 Sep;70(3):529-37. doi: 10.1016/j.eururo.2016.02.036. Epub 2016 Mar 3.

41.

Recommendations for future development of contractility and obstruction nomograms for women. ICI-RS 2014.

Rademakers K, Apostolidis A, Constantinou C, Fry C, Kirschner-Hermanns R, Oelke M, Parsons B, Nelson P, Valentini F, Gammie A.

Neurourol Urodyn. 2016 Feb;35(2):307-11. doi: 10.1002/nau.22776. Review.

PMID:
26872573
42.

What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014.

Visco AG, Fraser MO, Newgreen D, Oelke M, Cardozo L.

Neurourol Urodyn. 2016 Feb;35(2):288-92. doi: 10.1002/nau.22795. Review.

PMID:
26872569
43.

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, Porst H, Roehrborn C, Stief C, Giuliano F.

Eur Urol. 2016 Jul;70(1):124-133. doi: 10.1016/j.eururo.2015.12.048. Epub 2016 Jan 22. Review.

PMID:
26806655
44.

[Pharmacological treatment of benign prostatic hyperplasia].

Oelke M, Martinelli E.

Urologe A. 2016 Jan;55(1):81-94; quiz 95-6. doi: 10.1007/s00120-015-0011-3. German.

PMID:
26676726
45.

Detrusor underactivity in men with lower urinary tract symptoms/benign prostatic obstruction: characterization and potential impact on indications for surgical treatment of the prostate.

Rademakers KL, van Koeveringe GA, Oelke M.

Curr Opin Urol. 2016 Jan;26(1):3-10. doi: 10.1097/MOU.0000000000000246. Review.

PMID:
26574876
46.

[S2e guideline of the German urologists: Instrumental treatment of benign prostatic hyperplasia].

Bschleipfer T, Bach T, Berges R, Dreikorn K, Gratzke C, Madersbacher S, Michel MS, Muschter R, Oelke M, Reich O, Tschuschke C, Höfner K.

Urologe A. 2016 Feb;55(2):195-207. doi: 10.1007/s00120-015-3983-0. German.

PMID:
26518304
47.

[S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].

Höfner K, Bach T, Berges R, Dreikorn K, Gratzke C, Madersbacher S, Michel MS, Muschter R, Oelke M, Reich O, Tschuschke C, Bschleipfer T.

Urologe A. 2016 Feb;55(2):184-94. doi: 10.1007/s00120-015-3984-z. German.

PMID:
26518303
49.

Unravelling detrusor underactivity: Development of a bladder outlet resistance-Bladder contractility nomogram for adult male patients with lower urinary tract symptoms.

Oelke M, Rademakers KL, van Koeveringe GA; FORCE Research Group, Maastricht & Hannover.

Neurourol Urodyn. 2016 Nov;35(8):980-986. doi: 10.1002/nau.22841. Epub 2015 Jul 31.

PMID:
26235823
50.

Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study.

Robinson D, Oelke M, Khullar V, Wijkstra H, Tretter R, Stow B, Compion G, Tubaro A.

Neurourol Urodyn. 2016 Sep;35(7):819-25. doi: 10.1002/nau.22808. Epub 2015 Jul 21.

PMID:
26199198

Supplemental Content

Support Center